News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
Ronco succeeds Dr. Christine Dingivan, who will now serve as a senior advisor to Executive Chairman Sastry Chilukuri
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Subscribe To Our Newsletter & Stay Updated
